Axis Labs Adipo-X + Xtract

ADIPO-X® v2.0 Advanced Fat-Loss & Powerful Energy

Let's face it, life is a competition. In the gym, on the contest stage, at the beach, or your next class reunion, don't let your competition upstage you! No matter what your game, you play to win! Come in shredded with Competition Strength ADIPO-X® Version 2.0. ADIPO-X® v2.0 is the strongest fat shredding, skin-thinning, high-energy fat loss product available. Achieve "contest-like" condition with the most comprehensive, most complete get-lean formula available!

A NEW ADIPO-X®? WHY IMPROVE ON PERFECTION?

ADIPO-X®, our original, best-selling Fat Incinerator, was specifically formulated to attack fat more aggressively than old school ephedrine. And it did. Powerful and strong, ADIPO-X® worked like no other product on the market before it.

ADIPO-X® original contains potent thermogenic components and effective metabolic up-regulators in addition to several key fat mobilizing and appetite-suppressing agents. The original ADIPO-X® formulation is a very formidable weapon in the war on fat. So why did we even think about changing it?

YOU ASKED FOR IT, SO WE DID IT!

The original ADIPO-X® has been so successful for us we were surprised when a few of you asked for more...

For those of you who want the push over the cliff, the final word in fat loss, we, made a few subtle but significant changes that make ADIPO-X® Version 2.0 even better than its powerful predecessor.

SIMPLY STRONGER THAN BIG BROTHER...

ATTACK FAT FROM ALL ANGLES! Like it's older brother, this next generation formula utilizes multiple metabolic pathways to target fat loss, allowing the body to maintain continuous, increased and ongoing fat-burning and coaxing the body to use fat first for fuel while sparing the breakdown of precious muscle tissue.

ADIPO-X® v2.0's clinically proven ingredients ramp up fat loss by stimulating the body's primary fat-mobilizing hormones, epinephrine and norepinephrine, to mobilize fatty acids from storage to be used for energy.

ADIPO-X® v2.0 clinically-proven, multi-pronged attack on fat works in the following ways:

1. Stimulates increased release of epinephrine and norepinephrine, the body's primary fat loss hormones. Epinephrine and norepinephrine stimulate the beta adrenergic receptors of the fat cell, or adipocyte, triggering the mobilization of fatty acids from storage areas within the fat cells to be used for energy. This process is called lipolysis.

2. Sustains lipolysis by "protecting" the chemical messenger, cAMP from breakdown. The secondary chemical messenger within the adipocyte that triggers the release of fatty acids and their utilization for energy is called cAMP, or cyclic AMP. ADIPO-X® v2.0 protects cAMP from breakdown and keeps it alive longer within the cell, prolonging the fat loss process.

3. Prevents these fat loss hormones from being broken down, allowing for continuous fat loss. ADIPO-X® v2.0, like it's older brother, contains several ingredients that prevent the breakdown of the fat-burning adrenal hormones by inhibiting the enzymes COMT and MAO. This prolongs the life of epinephrine and norepinephrine in the body, to prolong the fat burning process.

4. Inhibits alpha-receptor activation. While targeting the Beta receptors of the fat cell stimulated the release and burn of stored fat within the adipocyte, stimulation of the alpha adrenergic receptors will shut down the process. ADIPO-X® v2.0 contains several ingredients included to prevent activation of the alpha adrenergic receptors, to prevent the slow down of the fat loss process.

5. Increases the thermogenic uncoupling process. ADIPO-X® v2.0 supports thermogenesis, or the utilization of the fatty acids for energy, once the stored fat released.

6. Blocks fat storage. The ingredients in ADIPO-X® v2.0 inhibit the synthesis from new fat by blocking the body's chemical process for storing fat.

7. Ramps up metabolism by supporting thyroid function. ADIPO-X® v2.0 supports the function of the thyroid, the body's metabolic regulation center. By ensuring proper thyroid function, metabolism can be enhanced, and ultimately fat loss is maximized.

SO WHAT'S NEW?

In addition to all that was great about the original formula, ADIPO-X® v2.0 contains powerful new components that aid in process of maximizing fat loss while improving performance, energy and focus.

Chocamine: a chemical derivative of chocolate, Chocamine contains specific key natural agents that mimic brain chemicals that govern appetite, alertness and mood. Chocamine is the reason why chocolate can produce euphoria, suppress appetite and have a stimulant-like effect.

Glucomannan (AmorphophallusKnojac): a soluble fiber derivative that helps with appetite control. Clinical studies show that Glucomannan can help curb appetite and contribute to fat loss. Glucomannan may also improve total cholesterol levels.

1,3-Dimethylamylamine: is a derivative of geranium oil which resembles the body's own chemical messenger epinephrine (adrenaline). Like adrenaline, 1,3-Dimethylamylamine is a powerful CNS stimulant increasing energy and clarity, especially valuable to athletes during calorie restriction or when a high level of focus is needed. Most importantly, it is also thought that 1,3-Dimethylamylamine works through a similar chemical pathway as ephedrine, causing a rise in cAMP, the chemical messenger that triggers fat release.

Yohimbine HCL: Yohimbine is an alpha receptor antagonist. As such, this potent herbal derivative helps with fat loss by helping to keep the lipolytic process rolling, ongoing 24/7. This is especially true in the body regions that are typically "problem areas" specific to gender. In women, these areas include the hips, thighs and butt, in med, it includes the midsection. Typically, fat cells in these gender-specific problem areas have a greater concentration of alpha receptors, compared to cells in other areas of the body. Yohimbine helps maximize fat loss especially in these areas.

This is especially true in the body regions that are typically "problem areas" specific to gender. In women, these areas include the hips, thighs and butt, in med, it includes the midsection. Typically, fat cells in these gender-specific problem areas have a greater concentration of alpha receptors, compared to cells in other areas of the body. Yohimbine helps maximize fat loss especially in these areas. ADIPO-X® v2.0 contains the hydrochloride, standardized version of Yohimbine, which ensures maximum potency with each and every single dose.

Now available! Our limited edition "Competition Kit!"

Achieve that professional HARD, LEAN and DRY "contest" condition!

Each Competition kit contains a complete 30-Day "competition cycle":

XTRACT is not simply some mild tealeaf and greens concoction that may or may not work for you.

XTRACT is a whopping 1,700mg of the most pure, most potent fluid-extracting agents available in nature. With more actives per dose, XTRACT will dry you out fast and tight. But, to ensure the water stays where you need it and is pulled only from where you don't (under the skin), XTRACT also provides a full 1,000mg of balanced electrolytes.

XTRACT is the most-effective herbal diuretic formula available. For high-definition fluid control, there is no stronger product. Together with ADIPO-X® v2.0, The Competition Kit will do more in 30-days to change the look of your body than any other product you've ever used! We guarantee it!

No matter what the occasion or event, life is a competitive sport - play to win!

Use what the pro's use and show up shredded! Get shrink-wrapped and skin-tight with ADIPO-X® Competition Kit! No other formula is stronger for fat loss, appetite control and high-power energy!

Other Ingredients: Gelatin, magnesium stearate and silica.

Directions: As a dietary supplement, start with a 1 capsule serving to evaluate tolerance and gradually increase to a full 2 capsule serving. Take one serving with 8 oz of water 30 to 60 minutes prior to breakfast on an empty stomach and an additional serving in the early afternoon on an empty stomach. Do not exceed 4 capsules in a 24 hour period. Do not take 6 hours prior to bed because ADIPO-X™ may interfere with sleep. Read entire label before using.

Store in a cool place. Protect from heat, light and moisture.

WARNING: KEEP OUT OF REACH OF CHILDREN. Not for use by individuals under the age of 18 or elderly. Consult a physician before using this or any dietary supplement. Do not use if pregnant, nursing or chronically ill. This product is not intended for individuals who are at risk of or have been treated for digestive disorders, high blood pressure, heart disease, thyroid disease, depression or other psychiatric conditions, renal disease, reoccurring headaches, spasms, has asthma or taking asthma medication. Discontinue use and consult your health care professional if dizziness,  nausea, sleeplessness, tremors, nervousness, headache, or heart palpitations occur.  Do not exceed recommended dose.

Manufactured with pride in the USA.
ADIPO-X® is a registered trademark of Axis Labs®.

References:
Akiba, T., K. Yaguchi, et al. (2004). "Inhibitory mechanism of caffeine on insulin-stimulated glucose uptake in adipose cells." Biochem Pharmacol 68(10): 1929-37.
Banderet, L. E. and H. R. Lieberman (1989). "Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans." Brain Res Bull 22(4): 759-62.
Belza, A., E. Frandsen, et al. (2007). "Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects." Int J Obes (Lond) 31(1): 121-30.
Bhardwaj, R. K., H. Glaeser, et al. (2002). "Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4." J Pharmacol Exp Ther 302(2): 645-50.
Borea, P. A., K. Varani, et al. (1994). "Full and partial agonistic behaviour and thermodynamic binding parameters of adenosine A1 receptor ligands." Eur J Pharmacol 267(1): 55-61.
Carlson, L. A., R. W. Butcher, et al. (1970). "Fat mobilizing lipolysis and levels of cyclic AMP in human and dog adipose tissue." Acta Med Scand 187(6): 525-8.
Chanadiri, T., T. Sanikidze, et al. (2005). "[Effectiveness of green tea catechines for the correction of the alimentary obesity in the experiment]." Georgian Med News(126): 61-3.
Chaudhry, A. and J. G. Granneman (1991). "Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat." Am J Physiol 261(2 Pt 2): R403-11.
Chaudhry, A. and J. G. Granneman (1997). "Effect of hypothyroidism on adenylyl cyclase activity and subtype gene expression in brown adipose tissue." Am J Physiol 273(2 Pt 2): R762-7.
Chen, D., C. Y. Wang, et al. (2005). "Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies." Biochem Pharmacol 69(10): 1523-31.
Choi, H. S. (2006). "Lipolytic effects of citrus peel oils and their components." J Agric Food Chem 54(9): 3254-8.
Cui, J. and J. Himms-Hagen (1992). "Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats." Am J Physiol 262(4 Pt 2): R568-73.
Currie, P. J. and L. M. Wilson (1992). "Yohimbine attenuates clonidine-induced feeding and macronutrient selection in genetically obese (ob/ob) mice." Pharmacol Biochem Behav 43(4): 1039-46.
Diepvens, K., E. M. Kovacs, et al. (2005). "Effect of green tea on resting energy expenditure and substrate oxidation during weight loss in overweight females." Br J Nutr 94(6): 1026-34.
Diepvens, K., K. R. Westerterp, et al. (2007). "Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea." Am J Physiol Regul Integr Comp Physiol 292(1): R77-85.
Dolgacheva, L. P., B. B. Abzhalelov, et al. (2003). "Norepinephrine induces slow calcium signalling in murine brown preadipocytes through the beta-adrenoceptor/cAMP/protein kinase A pathway." Cell Signal 15(2): 209-16.
Dulloo, A. G., C. Duret, et al. (1999). "Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans." Am J Clin Nutr 70(6): 1040-5.
Dulloo, A. G., J. Seydoux, et al. (2000). "Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity." Int J Obes Relat Metab Disord 24(2): 252-8.
Galitzky, J., M. Lafontan, et al. (1993). "Role of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human adipose tissue." J Clin Invest 91(5): 1997-2003.
Galitzky, J., D. Riviere, et al. (1990). "Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers." Eur J Clin Pharmacol 39(5): 447-51.
Galitzky, J., M. Taouis, et al. (1988). "Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers." Eur J Clin Invest 18(6): 587-94.
Gelenberg, A. J., C. J. Gibson, et al. (1982). "Neurotransmitter precursors for the treatment of depression." Psychopharmacol Bull 18(1): 7-18.
Gomez-Ambrosi, J., G. Fruhbeck, et al. (2001). "Divergent effects of an alpha2-adrenergic antagonist on lipolysis and thermogenesis: interactions with a beta3-adrenergic agonist in rats." Int J Mol Med 8(1): 103-9.
Grunfeld, C. and J. K. Shigenaga (1984). "Nicotinamide and other inhibitors of ADP-ribosylation block deoxyglucose uptake in cultured cells." Biochem Biophys Res Commun 123(2): 785-91.
Han, L. K., X. J. Gong, et al. (2005). "[Antiobesity actions of Zingiber officinale Roscoe]." Yakugaku Zasshi 125(2): 213-7.
Harmer, C. J., S. F. McTavish, et al. (2001). "Tyrosine depletion attenuates dopamine function in healthy volunteers." Psychopharmacology (Berl) 154(1): 105-11.
Hellstrom, L., S. Rossner, et al. (1997). "Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity--a metabolic predictor of weight loss in obese subjects." Int J Obes Relat Metab Disord 21(4): 314-20.
Ho, R. and Q. H. Shi (1982). "Forskolin as a novel lipolytic agent." Biochem Biophys Res Commun 107(1): 157-64.
Ho, R. J. (1970). "Dependence of hormone-stimulated lipolysis on ATP and cyclic AMP levels in fat cells." Horm Metab Res 2: Suppl 2:83-7.
Honnor, R. C., G. S. Dhillon, et al. (1985). "cAMP-dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady-state relationship with lipolytic and antilipolytic modulators." J Biol Chem 260(28): 15130-8.
Howald, H. and J. Decombaz (1983). "Nutrient intake and energy regulation in physical exercise." Experientia Suppl 44: 77-88.
Imbeault, P., D. Prud'Homme, et al. (2000). "Adipose tissue metabolism in young and middle-aged men after control for total body fatness." J Clin Endocrinol Metab 85(7): 2455-62.
Imbeault, P., A. Tremblay, et al. (2000). "beta-adrenoceptor-stimulated lipolysis of subcutaneous abdominal adipocytes as a determinant of fat oxidation in obese men." Eur J Clin Invest 30(4): 290-6.
Kawada, T., K. Hagihara, et al. (1986). "Effects of capsaicin on lipid metabolism in rats fed a high fat diet." J Nutr 116(7): 1272-8.
Kawada, T., T. Watanabe, et al. (1986). "Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization." Proc Soc Exp Biol Med 183(2): 250-6.
Kirchgessner, M., D. A. Roth-Maier, et al. (1995). "[B-vitamins (thiamine, vitamin b6, pantothenic acid) in lean muscle tissue of growing cattle of the German Simmental breed under different feeding intensities]." Z Lebensm Unters Forsch 201(1): 20-4.
Kobayashi, A., T. Osaka, et al. (1998). "Capsaicin activates heat loss and heat production simultaneously and independently in rats." Am J Physiol 275(1 Pt 2): R92-8.
Kucio, C., K. Jonderko, et al. (1991). "Does yohimbine act as a slimming drug?" Isr J Med Sci 27(10): 550-6.
Lambert, J. D., J. Hong, et al. (2004). "Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice." J Nutr 134(8): 1948-52.
Le Corre, P., G. Dollo, et al. (1999). "Biopharmaceutics and metabolism of yohimbine in humans." Eur J Pharm Sci 9(1): 79-84.
Lejeune, M. P., E. M. Kovacs, et al. (2003). "Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects." Br J Nutr 90(3): 651-59.
Lemonnier, D., P. de Gasquet, et al. (1974). "Effect of dietary vitamin B level on fat storage, adipose tissue cellularity and energy expenditure in rats and mice fed a high-fat diet." Nutr Metab 16(1): 15-29.
Lieberman, H. R., J. H. Georgelis, et al. (2005). "Tyrosine prevents effects of hyperthermia on behavior and increases norepinephrine." Physiol Behav 84(1): 33-8.
Lin, Z., Y. Liao, et al. (2007). "Amides from Piper nigrum L. with dissimilar effects on melanocyte proliferation in-vitro." J Pharm Pharmacol 59(4): 529-36.
Litosch, I., T. H. Hudson, et al. (1982). "Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes." Mol Pharmacol 22(1): 109-15.
Lu, H., X. Meng, et al. (2003). "Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate." Drug Metab Dispos 31(5): 572-9.
Malbon, C. C. and M. P. Graziano (1983). "Adenosine deaminase normalizes cyclic AMP responses of hypothyroid rat fat cells to forskolin, but not beta-adrenergic agonists." FEBS Lett 155(1): 35-8.
Masuda, Y., S. Haramizu, et al. (2003). "Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog." J Appl Physiol 95(6): 2408-15.
McNamara, F. N., A. Randall, et al. (2005). "Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1)." Br J Pharmacol 144(6): 781-90.
Melnyk, A. and J. Himms-Hagen (1995). "Resistance to aging-associated obesity in capsaicin-desensitized rats one year after treatment." Obes Res 3(4): 337-44.
Mochizuki, M. and N. Hasegawa (2004). "Effects of green tea catechin-induced lipolysis on cytosol glycerol content in differentiated 3T3-L1 cells." Phytother Res 18(11): 945-6.
Morimoto, C., Y. Satoh, et al. (2005). "Anti-obese action of raspberry ketone." Life Sci 77(2): 194-204.
Muroyama, K., S. Murosaki, et al. (2003). "Effects of intake of a mixture of thiamin, arginine, caffeine, and citric acid on adiposity in healthy subjects with high percent body fat." Biosci Biotechnol Biochem 67(11): 2325-33.
Muroyama, K., S. Murosaki, et al. (2003). "Anti-obesity effects of a mixture of thiamin, arginine, caffeine, and citric acid in non-insulin dependent diabetic KK mice." J Nutr Sci Vitaminol (Tokyo) 49(1): 56-63.
Ohnuki, K., S. Haramizu, et al. (2001). "Administration of capsiate, a non-pungent capsaicin analog, promotes energy metabolism and suppresses body fat accumulation in mice." Biosci Biotechnol Biochem 65(12): 2735-40.
Ostman, J. (1964). "Effect Of Nicotinic Acid On The Fatty Acid Metabolism Of Adipose Tissue In Alloxan Diabetic Rats." Metabolism 13: 675-80.
Ostman, J. (1965). "Inhibitory Effect Of Nicotinic Acid On Fat Mobilization In Alloxan-Diabetic Rats. Ii. A Comparison Of The Effect Of Nicotinic Acid And Salicylate On The Fatty Acid Metabolism And Glucose Uptake By Adipose Tissue In Vitro." Acta Med Scand 177: 623-9.
Papadelis, C., C. Kourtidou-Papadeli, et al. (2003). "Effects of mental workload and caffeine on catecholamines and blood pressure compared to performance variations." Brain Cogn 51(1): 143-54.
Rababah, T. M., N. S. Hettiarachchy, et al. (2004). "Total phenolics and antioxidant activities of fenugreek, green tea, black tea, grape seed, ginger, rosemary, gotu kola, and ginkgo extracts, vitamin E, and tert-butylhydroquinone." J Agric Food Chem 52(16): 5183-6.
Razzoli, G. (1972). "[Effect of coffee on deposit lipids]." Minerva Med 63(61): 3361-2.
Roberts, S. A., J. M. Thorpe, et al. (2001). "Tyrosine requirement of healthy men receiving a fixed phenylalanine intake determined by using indicator amino acid oxidation." Am J Clin Nutr 73(2): 276-82.
Scarpace, P. J., L. A. Baresi, et al. (1987). "Modulation of receptors and adenylate cyclase activity during sucrose feeding, food deprivation, and cold exposure." Am J Physiol 253(6 Pt 1): E629-35.
Schimmel, R. J. (1980). "Interactions between catecholamines, methyl xanthines and adenosine in regulation of cyclic AMP accumulation in hamster adipocytes." Biochim Biophys Acta 629(1): 83-94.
Shixian, Q., B. VanCrey, et al. (2006). "Green tea extract thermogenesis-induced weight loss by epigallocatechin gallate inhibition of catechol-O-methyltransferase." J Med Food 9(4): 451-8.
Simon, E., M. T. Macarulla, et al. (2005). "Body fat-lowering effect of conjugated linoleic acid is not due to increased lipolysis." J Physiol Biochem 61(2): 363-9.
Srinivasan, M. R. and M. N. Satyanarayana (1989). "Effect of capsaicin on skeletal muscle lipoprotein lipase in rats fed high fat diet." Indian J Exp Biol 27(10): 910-2.
Szallasi, A. (2005). "Piperine: researchers discover new flavor in an ancient spice." Trends Pharmacol Sci 26(9): 437-9.
Szilagyi, G., Z. Nagy, et al. (2005). "Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study." J Neurol Sci 229-230: 275-84.
Tam, S. W., M. Worcel, et al. (2001). "Yohimbine: a clinical review." Pharmacol Ther 91(3): 215-43.
Tapsell, L. C., I. Hemphill, et al. (2006). "Health benefits of herbs and spices: the past, the present, the future." Med J Aust 185(4 Suppl): S4-24.
Tornqvist, H., L. Krabisch, et al. (1972). "Rapid assay for hormone-sensitive lipase activity of adipose tissue." J Lipid Res 13(3): 424-6.
Tsi, D., A. K. Nah, et al. (2003). "Clinical study on the combined effect of capsaicin, green tea extract and essence of chicken on body fat content in human subjects." J Nutr Sci Vitaminol (Tokyo) 49(6): 437-41.
Verma, S. K. and A. Bordia (2001). "Ginger, fat and fibrinolysis." Indian J Med Sci 55(2): 83-6.
Walldius, G. and G. Wahlberg (1985). "Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis." Adv Exp Med Biol 183: 281-93.
Westerterp-Plantenga, M., K. Diepvens, et al. (2006). "Metabolic effects of spices, teas, and caffeine." Physiol Behav 89(1): 85-91.
Wolfram, S., Y. Wang, et al. (2006). "Anti-obesity effects of green tea: from bedside to bench." Mol Nutr Food Res 50(2): 176-87.
Wu, A. H., C. C. Tseng, et al. (2003). "Tea intake, COMT genotype, and breast cancer in Asian-American women." Cancer Res 63(21): 7526-9.
Yoshida, T., K. Yoshioka, et al. (1988). "Effects of capsaicin and isothiocyanate on thermogenesis of interscapular brown adipose tissue in rats." J Nutr Sci Vitaminol (Tokyo) 34(6): 587-94.
Zhang, L. L., D. Yan Liu, et al. (2007). "Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity." Circ Res 100(7): 1063-70.